Treatment of experimental intravitreal fibrin with tissue plasminogen activator.
Lambrou F H, Snyder R W, Williams G A, Lewandowski M
AI Summary
In rabbits, intravitreal tPA safely and rapidly cleared experimental fibrin clots, suggesting its potential for treating human intravitreal fibrin without toxicity.
Abstract
We produced experimental intravitreal fibrin clots in rabbits that had previous gas compression of the vitreous or intact vitreous. Twenty-four hours after production of fibrin, the eyes were injected with 25 micrograms of tissue plasminogen activator or physiologic irrigation solution. In the gas compression group (n = 11), all tissue plasminogen activator-treated eyes cleared within six hours of injection; complete clearing was not seen until six days in the physiologic irrigation solution-treated eyes (n = 9). A similar response was seen in the intact vitreous group. No evidence of toxicity was observed as measured by slit-lamp biomicroscopy, intraocular pressure, corneal thickness, electroretinography, or histopathologic examination.
MeSH Terms
Related Articles5
Effects of nicotinamide supplementation in normal-tension glaucoma: a crossover placebo-controlled randomised clinical trial.
Randomized Controlled TrialAntihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial.
Randomized Controlled TrialUveitis in Adults: A Review.
ReviewEffectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: A systematic review and network meta-analysis of randomized controlled trials.
Systematic ReviewAssociation of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.
Observational StudyIs this article assigned to the wrong chapter(s)? Let us know.